Mary Jo Fidler, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
   Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi P.
   Anticancer Res. 2012
   2012 May
   32(5):1705-10.
   
2. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.
   Fidler MJ, Shersher DD, Borgia JA, Bonomi P.
   Ther Adv Med Oncol. 2012
   2012 Mar
   4(2):51-60. doi: 10.1177/1758834011427576.
   
3. Prognostic Significance of Weight Gain During Definitive Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
   Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P.
   Clin Lung Cancer. 2012
   2012 Dec 20. doi:pii: S1525-7304(12)00263-X. 10.1016/j.cllc.2012.10.009. [Epub ahead of print]
   
4. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
   Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P.
   J Thorac Oncol.
   2011 Jun
   6(6):1079-86.
   
5. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer
   Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ
   Lung Cancer
   2011 Feb
   71(2):186-90
   
6. Weight Gain in Advanced Non-Small-Cell Lung Cancer Patients During Treatment With Split-Course Concurrent Chemoradiotherapy is Associated With Superior Survival
   Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP
   Int J Radiat Oncol Biol Phys
   2010 Oct 5
   
7. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer
   Batus M, Fidler MJ, Bonomi PD
   Expert Rev Anticancer Ther
   2010 Oct
   10(10):1589-99
   
8. Immunotherapy to overcome lung tumor cell-induced escape from immunosurveillance
   Plate JM, Fidler MJ
   Immunotherapy
   2010 Nov
   2(6):757-60
   
9. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients
   Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J
   Int J Cancer
   2010 Apr 1
   126(7):1630-9
   
10. Treatment of locally advanced non-small cell lung cancer
    Fidler MJ, Kim AW, Zusag T, Bonomi P
    Clin Adv Hematol Oncol
    2009 Jul
    7(7):455-64, 479-80
    
11. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J 4th, Buckingham L, Kaiser K, Basu S, Bonomi P
    Clin Cancer Res
    2008 Apr 1
    14(7):2088-94
    

• To watch a brief video of Mary Fidler, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• People have asked me, “Well, do you ever get bored seeing the same thing day after day?” — especially some community doctors who do a little bit of everything. They’ll ask me, “Do you ever get bored?” And the answer is, “No,” because every patient’s different, every patient’s circumstance is a little bit different.

  It’s motivating to watch people feel better. That’s certainly the best motivation you can have. Being in oncology itself, I think it’s a fascinating field and pretty rapidly changing. I think it was pretty similar, stagnant for a number of years. But in the last five or six years, so many new targets, so many new pathways, so many new options are out there. It’s really a fascinating field to be a part of.